FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113550321> ?p ?o ?g. }

• W2113550321 endingPage "869" @default.
• W2113550321 startingPage "861" @default.
• W2113550321 abstract "Cholangiocarcinoma is markedly resistant to chemotherapy and has a dismal prognosis, but its mechanism of drug resistance is unknown. This study examines whether glutathione <i>S</i>-transferase-π (GSTP1-1) is involved in resistance to anticancer drugs in cholangiocarcinoma and whether GSTP1-1-specific inhibitors can overcome this resistance. First, immunohistochemical examination disclosed strong staining of all our 17 cholangiocarcinoma specimens for GSTP1-1, irrespective of histological type. Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants. We next synthesized GSTP1-1-specific inhibitors by elongating the carbon chain of the ethylester at the <i>N</i>-terminal of γ-glutamyl-<i>S</i>-benzylcysteinyl-phenylglycyl diethylester and performed a pharmacokinetic study on them. Of six GSTP1-1 inhibitors tested, <i>O</i>¹-hexadecyl-γ-glutamyl-<i>S</i>-benzylcysteinyl-d-phenylglycine ethylester (C16C2) showed the smallest volume of central compartment and smallest volume of distribution at steady state and the second smallest clearance, being the most effective inhibitor in vivo. The IC₅₀ value of ADR or 4-HC for HuCCT1 cells decreased greater by treatment with C16C2 in a dose-dependent manner, paralleling the decrease in GSTP1-1 activity, than that of ADR or 4-HC alone. The antitumor activity of ADR or cyclophosphamide was clearly enhanced by combination therapy with C16C2 in a xenograft model. In conclusion, our results demonstrated that GSTP1-1 is a resistance factor for anticancer drugs in cholangiocarcinoma and that C16C2, a GSTP1-1-specific inhibitor, is a potent agent against the resistance." @default.
• W2113550321 created "2016-06-24" @default.
• W2113550321 creator A5000591714 @default.
• W2113550321 creator A5001929126 @default.
• W2113550321 creator A5002923095 @default.
• W2113550321 creator A5023559384 @default.
• W2113550321 creator A5028218002 @default.
• W2113550321 creator A5030298726 @default.
• W2113550321 creator A5054203101 @default.
• W2113550321 creator A5054498346 @default.
• W2113550321 creator A5056407210 @default.
• W2113550321 creator A5058075352 @default.
• W2113550321 creator A5090641081 @default.
• W2113550321 date "2003-06-12" @default.
• W2113550321 modified "2023-10-03" @default.
• W2113550321 title "Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione<i>S</i>-Transferase-π-Specific Inhibitor<i>O</i>¹-Hexadecyl-γ-glutamyl-<i>S</i>-benzylcysteinyl-D-phenylglycine Ethylester" @default.
• W2113550321 cites W1581414347 @default.
• W2113550321 cites W1967648318 @default.
• W2113550321 cites W1979836689 @default.
• W2113550321 cites W1981485296 @default.
• W2113550321 cites W1982693874 @default.
• W2113550321 cites W2004621494 @default.
• W2113550321 cites W2007902782 @default.
• W2113550321 cites W2034041873 @default.
• W2113550321 cites W2053515611 @default.
• W2113550321 cites W2053642508 @default.
• W2113550321 cites W2054777336 @default.
• W2113550321 cites W2061997406 @default.
• W2113550321 cites W2078797029 @default.
• W2113550321 cites W2080416871 @default.
• W2113550321 cites W2084665581 @default.
• W2113550321 cites W2099942653 @default.
• W2113550321 cites W215606578 @default.
• W2113550321 cites W2169731354 @default.
• W2113550321 cites W2332605220 @default.
• W2113550321 cites W2951513243 @default.
• W2113550321 cites W4241218818 @default.
• W2113550321 doi "https://doi.org/10.1124/jpet.103.052696" @default.
• W2113550321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12805482" @default.
• W2113550321 hasPublicationYear "2003" @default.
• W2113550321 type Work @default.
• W2113550321 sameAs 2113550321 @default.
• W2113550321 citedByCount "55" @default.
• W2113550321 countsByYear W21135503212012 @default.
• W2113550321 countsByYear W21135503212013 @default.
• W2113550321 countsByYear W21135503212014 @default.
• W2113550321 countsByYear W21135503212015 @default.
• W2113550321 countsByYear W21135503212016 @default.
• W2113550321 countsByYear W21135503212017 @default.
• W2113550321 countsByYear W21135503212018 @default.
• W2113550321 countsByYear W21135503212019 @default.
• W2113550321 countsByYear W21135503212020 @default.
• W2113550321 countsByYear W21135503212021 @default.
• W2113550321 countsByYear W21135503212022 @default.
• W2113550321 countsByYear W21135503212023 @default.
• W2113550321 crossrefType "journal-article" @default.
• W2113550321 hasAuthorship W2113550321A5000591714 @default.
• W2113550321 hasAuthorship W2113550321A5001929126 @default.
• W2113550321 hasAuthorship W2113550321A5002923095 @default.
• W2113550321 hasAuthorship W2113550321A5023559384 @default.
• W2113550321 hasAuthorship W2113550321A5028218002 @default.
• W2113550321 hasAuthorship W2113550321A5030298726 @default.
• W2113550321 hasAuthorship W2113550321A5054203101 @default.
• W2113550321 hasAuthorship W2113550321A5054498346 @default.
• W2113550321 hasAuthorship W2113550321A5056407210 @default.
• W2113550321 hasAuthorship W2113550321A5058075352 @default.
• W2113550321 hasAuthorship W2113550321A5090641081 @default.
• W2113550321 hasConcept C104317684 @default.
• W2113550321 hasConcept C114851261 @default.
• W2113550321 hasConcept C126322002 @default.
• W2113550321 hasConcept C150903083 @default.
• W2113550321 hasConcept C181199279 @default.
• W2113550321 hasConcept C185592680 @default.
• W2113550321 hasConcept C202751555 @default.
• W2113550321 hasConcept C207001950 @default.
• W2113550321 hasConcept C2776694085 @default.
• W2113550321 hasConcept C2776755627 @default.
• W2113550321 hasConcept C2776907368 @default.
• W2113550321 hasConcept C2778239845 @default.
• W2113550321 hasConcept C2780122483 @default.
• W2113550321 hasConcept C538909803 @default.
• W2113550321 hasConcept C54009773 @default.
• W2113550321 hasConcept C54355233 @default.
• W2113550321 hasConcept C55493867 @default.
• W2113550321 hasConcept C71924100 @default.
• W2113550321 hasConcept C81885089 @default.
• W2113550321 hasConcept C86803240 @default.
• W2113550321 hasConcept C89423630 @default.
• W2113550321 hasConcept C98274493 @default.
• W2113550321 hasConceptScore W2113550321C104317684 @default.
• W2113550321 hasConceptScore W2113550321C114851261 @default.
• W2113550321 hasConceptScore W2113550321C126322002 @default.
• W2113550321 hasConceptScore W2113550321C150903083 @default.
• W2113550321 hasConceptScore W2113550321C181199279 @default.
• W2113550321 hasConceptScore W2113550321C185592680 @default.
• W2113550321 hasConceptScore W2113550321C202751555 @default.
• W2113550321 hasConceptScore W2113550321C207001950 @default.
• W2113550321 hasConceptScore W2113550321C2776694085 @default.

• next